Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases

被引:1183
作者
Wynn, Thomas A. [1 ]
机构
[1] NIAID, Immunogenet Sect, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1172/JCI31487
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Fibroproliferative diseases, including the pulmonary fibroses, systemic sclerosis, liver cirrhosis, cardiovascular disease, progressive kidney disease, and macular degeneration, are a leading cause of morbidity and mortality and can affect all tissues and organ systems. Fibrotic tissue remodeling can also influence cancer metastasis and accelerate chronic graft rejection in transplant recipients. Nevertheless, despite its enormous impact on human health, there are currently no approved treatments that directly target the mechanism(s) of fibrosis. The primary goals of this Review series on fibrotic diseases are to discuss some of the major fibroproliferative diseases and to identify the common and unique mechanisms of fibrogenesis that might be exploited in the development of effective antifibrotic therapies.
引用
收藏
页码:524 / 529
页数:6
相关论文
共 49 条
[1]   Scleroderma: from cell and molecular mechanisms to disease models [J].
Abraham, DJ ;
Varga, J .
TRENDS IN IMMUNOLOGY, 2005, 26 (11) :587-595
[2]   Toll-like receptor signalling [J].
Akira, S ;
Takeda, K .
NATURE REVIEWS IMMUNOLOGY, 2004, 4 (07) :499-511
[3]   Antifibrotic agents for liver disease [J].
Albanis, E ;
Friedman, SL .
AMERICAN JOURNAL OF TRANSPLANTATION, 2006, 6 (01) :12-19
[4]   Liver fibrosis [J].
Bataller, R ;
Brenner, DA .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (02) :209-218
[5]   ECM remodeling in hypertensive heart disease [J].
Berk, Bradford C. ;
Fujiwara, Keigi ;
Lehoux, Stephanie .
JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (03) :568-575
[6]   CIRCULATING FIBROCYTES DEFINE A NEW LEUKOCYTE SUBPOPULATION THAT MEDIATES TISSUE-REPAIR [J].
BUCALA, R ;
SPIEGEL, LA ;
CHESNEY, J ;
HOGAN, M ;
CERAMI, A .
MOLECULAR MEDICINE, 1994, 1 (01) :71-81
[7]   Mesenchymal stem cells as trophic mediators [J].
Caplan, Arnold I. ;
Dennis, James E. .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2006, 98 (05) :1076-1084
[8]   An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response [J].
Chiaramonte, MG ;
Donaldson, DD ;
Cheever, AW ;
Wynn, TA .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (06) :777-785
[9]   Regulation and function of the interleukin 13 receptor α 2 during a T helper cell type 2-dominant immune response [J].
Chiaramonte, MG ;
Mentink-Kane, M ;
Jacobson, BA ;
Cheever, AW ;
Whitters, MJ ;
Goad, MEP ;
Wong, A ;
Collins, M ;
Donaldson, DD ;
Grusby, MJ ;
Wynn, TA .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (06) :687-701
[10]   Studies of murine schistosomiasis reveal interleukin-13 blockade as a treatment for established and progressive liver fibrosis [J].
Chiaramonte, MG ;
Cheever, AW ;
Malley, JD ;
Donaldson, DD ;
Wynn, TA .
HEPATOLOGY, 2001, 34 (02) :273-282